BETA
Your AI-Trained Oncology Knowledge Connection!
Focused discussion on the CARD trial, which utilized cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer.
Stay up to date on practice-changing data in community practice.
CAN-2409 Boosts DFS in Localized Prostate Cancer with EBRT
Adding CAN-2409 to standard radiation therapy significantly improved disease-free survival and pathological complete response rates in intermediate-to-high-risk prostate cancer.
Read More
Transforming Prostate Cancer Care Through Personalized Medicine
Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.
Listen
Olaparib/Radium-223 Combo Boosts rPFS in Castration-Resistant Prostate Cancer
Olaparib and radium-223 bested radium-223 alone in radiographic progression-free survival in men with castration-resistant prostate cancer.
A Deep Dive Into the Evolving Landscape of Prostate Cancer
In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.
Darolutamide Improves Quality of Life in Metastatic Prostate Cancer
Darolutamide significantly delayed pain progression and improved overall well-being in patients with metastatic hormone-sensitive prostate cancer.
Niraparib Combo Lowers Progression Risk in HRR-Altered mCSPC
Niraparib with AAP cut the risk of progression or death by 37% in HRR-altered mCSPC, according to data from the AMPLITUDE trial.